Domov › Adenokarcinom požiralnika › Iowa
Klinične študije za Adenokarcinom požiralnika v Iowa
5 študij za Adenokarcinom požiralnika išče udeležence na lokacijah v Iowa.
Mesta v Iowa
Uradno besedilo študije (angleško)
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- Saint Anthony Regional Hospital, Carroll
- Mercy Hospital, Cedar Rapids
- in še 8
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT06203600mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- in še 12
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05677490A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Local Institution - 0268, Iowa City
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07221149Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- University of Iowa Hospitals and Clinics, Iowa City
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06324357Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Waukee
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07431281Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.